

Supplementary Table 4. Logistic regression analysis for the prevalence of sarcopenia, low LTI, and low HGS categorized according to the CKD stage

CKD-EPI sCr eGFR	Cystatin C/Cr ratio							
	Unadjusted		Model 1		Model 2		Model 3	
	OR (95% CI)	p-value	aOR (95% CI)	p-value	aOR (95% CI)	p-value	aOR (95% CI)	p-value
Sarcopenia								
≥60	5.65 (1.39–22.90)	0.02	3.26 (0.75–14.28)	0.12	2.13 (0.37–12.35)	0.4	1.31 (0.12–14.45)	0.83
<60, ≥45	3.46 (0.36–33.70)	0.29	0.55 (0.04–8.61)	0.67	1.66 (0.08–36.39)	0.75	1.14 (0.02–53.43)	0.95
<45, ≥30	12.99 (2.30–73.34)	0.004	4.51 (0.77–26.33)	0.09	5.74 (0.95–34.88)	0.06	5.08 (0.83–31.03)	0.08
<30	16.75 (3.38–82.91)	0.001	9.13 (1.65–50.41)	0.01	13.20 (1.89–92.47)	0.009	17.65 (1.72–180.88)	0.02
Low LTI								
≥60	18.86 (3.90–91.26)	<0.001	9.63 (1.94–47.84)	0.006	6.12 (1.14–32.86)	0.04	2.52 (0.32–19.79)	0.38
<60, ≥45	9.17 (1.16–72.57)	0.04	1.19 (0.10–14.77)	0.89	4.88 (0.21–114.88)	0.33	16.23 (0.28–930.55)	0.18
<45, ≥30	12.26 (2.24–67.29)	0.004	4.37 (0.77–24.91)	0.1	4.39 (0.77–25.11)	0.1	4.84 (0.82–28.62)	0.08
<30	17.47 (3.46–88.10)	0.001	11.84 (2.08–67.35)	0.005	17.61 (2.52–123.10)	0.004	30.49 (3.01–309.03)	0.004
Low HGS								
≥60	5.87 (1.60–21.55)	0.008	3.89 (1.02–14.88)	0.047	3.98 (0.91–17.33)	0.07	1.89 (0.38–9.47)	0.44
<60, ≥45	24.00 (2.91–197.81)	0.003	7.30 (0.68–78.71)	0.1	9.36 (0.66–132.96)	0.1	60.20 (1.86–1950.32)	0.02
<45, ≥30	34.02 (5.14–225.25)	<0.001	6.90 (0.95–50.10)	0.06	15.30 (1.67–140.06)	0.02	7.88 (0.84–73.57)	0.07
<30	7.20 (1.55–33.43)	0.01	1.30 (0.22–7.49)	0.77	0.65 (0.10–4.50)	0.66	0.26 (0.02–2.94)	0.28

Model 1: adjusted for age and body mass index. Model 2: adjusted for diabetes mellitus and hypertension in addition to model 1. Model 3: adjusted for albumin, hemoglobin, and eGFR in addition to model 2.

aOR, adjusted odds ratio; CI, confidence interval; CKD-EPI, Chronic Kidney Disease-Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; HGS, handgrip strength; LTI, lean tissue index; OR, odds ratio; sCr, serum creatinine.